FOSUN HEALTH Logo

Alzheimer's Disease & Dementia Diagnosis

catalogue

Alzheimer's Disease & Dementia Diagnosis

Alzheimer's Disease & Dementia Diagnosis

A dementia assessment is not a single test that returns a result. It is a sequence in which the common, cheap and reversible answers are dealt with first, and the confirmatory and expensive ones are reached only if they are still needed. This page sets out what each part of the assessment is actually for, how cognition is tested and what the scores mean, what imaging and biomarkers add, and why the exclusion list is the part that matters most to the person in front of you.

The question the assessment actually answers

An assessment is often imagined as a test for dementia. It is not, and the difference is practical: a positive or negative result is less useful than a cause. The assessment answers four questions, in this order, and the order is what keeps it efficient.

Question What answers it Why it comes in this position
Is there decline? A history from the person and from someone who knows them, plus documented cognitive testing Everything else depends on it. A complaint without documented impairment is not the same thing
Is it progressive, and how fast? A second assessment separated by months, and the trajectory from the history Progression is the defining feature. It cannot be established in a single visit
What is the cause? The phenotype, the imaging pattern, and where indicated the biomarkers This is where Alzheimer's is distinguished from the dementias around it, and where treatment is decided
What else is contributing? The medication review, and assessment of hearing, sleep, mood, pain and vascular risk Usually the largest reversible component, and usually the last thing considered

A number of diagnoses are made badly because the third question is answered before the fourth. The label is reached, the contributing causes are never looked for, and the person is left with a prognosis when what they needed was a hearing aid, a sleep study and three medicines stopped.

The history, and who has to be in the room

The single most informative part of a dementia assessment is not a scan. It is a history taken from two sources: the person, and someone who sees them regularly. Where only one of those is present, the assessment is poorer, and the reason is worth explaining.

The person's own account establishes what they have noticed, what they are worried about, and what they can still do. The informant's account establishes something the person often cannot: when it started, how fast it moved, and what has already been quietly taken over. That last item is the most reliable measure of functional decline available, and it is almost never volunteered because the family does not think of it as information.

The specific things worth establishing are these, and they are worth writing down before an appointment:

Element Why it changes the answer
The first domain affected Memory, language, visuospatial function and behaviour each point to a different underlying pathology and to different tests
Onset and tempo Years suggests neurodegeneration; weeks to months suggests an autoimmune, infectious, neoplastic or prion process, and those are urgent to exclude
Fluctuation Marked within-day variation points towards Lewy body disease or delirium rather than uncomplicated Alzheimer's
What the family has taken over, and when The most reliable functional measure available, and the one most often omitted
Every medicine, including over-the-counter The anticholinergic and sedative burden is a common contributor and it is reversible by subtraction
Falls, however trivial they seemed A subdural collection can present weeks later as cognitive change alone
Family history and age of onset in relatives Relevant to genetic counselling in early-onset disease, and to risk discussion in everyone
Mood, sleep, hearing and pain Each is treatable, each can present as cognitive decline, and each is commonly present alongside it

One practical note: the examination includes more than cognition. Gait, parkinsonism, eye movements, reflexes and the peripheral nervous system are all examined, because the findings there are often what separates one dementia from another.

Cognitive testing: what the scores are for

Cognitive testing does two things that a conversation cannot. It puts a number on the decline so that it can be compared later, and it maps which domains are affected. What it does not do is diagnose a cause, and it is worth saying so because both errors are common: a score treated as a diagnosis, and a normal score treated as reassurance.

A brief bedside screen — the MMSE, the MoCA, or an equivalent — is done in most clinics. It is quick, it is repeatable, and its main value is trend: the same test repeated at intervals tells you far more than any single number. It is also imperfect. Education, language, hearing, vision and culture all move the score, and a highly educated person can fall substantially and still score within the normal range.

Formal neuropsychological testing is worth doing when the picture is early, or atypical, or when the answer will change what happens next. It takes longer and it produces something a screen cannot: a profile. Which domains are impaired, and which are intact, is what separates a memory disorder from an attention disorder, a language disorder from an executive one, and genuine decline from depression or from a person who is simply anxious in a testing room.

Alongside cognition, function is assessed deliberately — managing money and medicines, using transport and the telephone, cooking and shopping, and later bathing, dressing and toileting. That functional line is what separates mild cognitive impairment from dementia, and it is what the care plan is built on.

Imaging: what each modality adds

Structural imaging is part of every new assessment, and it earns its place by answering three separate questions at once. It is not there to produce a picture for its own sake.

Modality What it shows What it does not do
Structural MRI The pattern and degree of atrophy, including whether the medial temporal regions are disproportionately affected; the burden of small vessel disease; and any structural or reversible cause It does not demonstrate Alzheimer's biology. Atrophy can be present without it, and the pattern can be ambiguous
CT A rapid exclusion of haemorrhage, a large lesion or a subdural collection, and ventricular size It is considerably less informative than MRI about atrophy patterns and small vessel disease, and it is a fallback rather than an equivalent
Amyloid PET Whether amyloid plaques are present in the brain, in living people It does not stage the disease, and a positive result in an unimpaired person is not a dementia diagnosis
FDG or perfusion PET The regional pattern of reduced metabolism, which separates one dementia from another when the phenotype is atypical It shows function rather than the specific protein pathology
Tau PET The distribution and burden of tau, which tracks more closely with symptoms than amyloid does Largely a research and selected-clinical tool; availability is limited
Dopamine transporter imaging Whether there is loss of the dopaminergic nerve terminals, which separates Lewy body disease from Alzheimer's when that is the question It answers one specific question and is ordered when that question is live

Two imaging findings are worth naming because they change management directly. Marked ventriculomegaly out of proportion to the atrophy, in someone with the gait and bladder triad, raises normal pressure hydrocephalus — the item on the differential that can improve after treatment. And a heavy burden of small vessel disease moves the plan towards vascular prevention, which is a treatment rather than an observation.

Biomarkers: amyloid, tau and what a positive result means

This is the largest change in the field in a generation. Alzheimer's used to be a diagnosis of exclusion, confirmed only at autopsy. It can now be identified in life, and increasingly from a blood sample. That change is real and it is useful, and it is also routinely over-read in both directions.

What is being measured falls into three groups. Amyloid — measured on PET or in cerebrospinal fluid — indicates that the amyloid arm of the pathology is present. Tau, and specifically phosphorylated tau, tracks more closely with symptoms and with stage. Neurodegeneration is measured on MRI as atrophy, and in blood as neurofilament light chain. The framework used in research combines them; in clinic, what matters is that amyloid and tau answer different questions.

Blood phosphorylated tau — p-tau217 in particular — has performed well enough in research settings to change who needs a lumbar puncture or a PET scan, and it is becoming part of clinical practice. It is a step change in accessibility, and it is also the reason the interpretation rule matters more than it used to.

The interpretation rule

Biomarkers confirm biology. They do not by themselves diagnose dementia. A positive amyloid or tau result in someone with normal cognition is not a diagnosis and does not mean decline is inevitable; it means the biology is present, which is a different statement. Conversely, a biomarker result is read alongside the phenotype and the examination, never as a standalone answer. And the test is worth doing when the result would change management — an atypical presentation, an unexpectedly young onset, or eligibility for antibody treatment — rather than as a screening test in someone with no symptoms.

The practical consequence of a confirmed result is narrow but real: it is the entry criterion for anti-amyloid antibody treatment, which is discussed on the treatment page. The consequence of a negative result is also real, and often undervalued — it redirects the assessment towards the other causes, several of which are treatable.

The exclusion list, and why it is not a formality

Every new cognitive assessment includes a defined set of blood tests and a medicines review. They are cheap, they are quick, and they find the answers that matter most, which is why they come first rather than last.

Cause Test If it is found
Vitamin B12 and folate deficiency Serum B12, folate, and where the picture is unclear methylmalonic acid Replacement. The cognitive change does not always fully reverse, which is the argument for testing early
Thyroid disease Thyroid function testing Treatment of the thyroid disorder, and reassessment afterwards
Metabolic and organ failure Electrolytes, calcium, glucose, kidney and liver function, full blood count Correction of the abnormality, which often produces a surprising improvement in attention
Infection and inflammation Directed by the history and examination; serology where indicated Treatment of the underlying infection. This is a small group and it is not one to miss
Medicine burden A review that calculates the anticholinergic and sedative load rather than listing drugs Reduction and substitution, with the cognitive effect reviewed weeks later
Sleep-disordered breathing Sleep history, and a sleep study where snoring or witnessed apnoea is present Treatment of the apnoea, which improves attention, mood and vascular risk together
Depression A structured mood assessment, which is part of the assessment rather than an extra Treatment, and a repeat of the cognitive testing afterwards before any label is settled
Normal pressure hydrocephalus Imaging, plus cerebrospinal fluid assessment Referral for the treatment decision. Of this list, the one most likely to improve substantially
Structural lesions Structural MRI, and CT where MRI is not possible Treatment of what is found; a subdural collection after a forgotten fall is the recurring example
Autoimmune encephalitis Antibody testing and cerebrospinal fluid analysis, where the tempo or the phenotype warrants it Immunotherapy rather than symptomatic treatment. Uncommon, treatable, and the reason tempo matters

Where the picture is incomplete, the honest position is an active differential with a date to review it rather than a premature label. That position has a real advantage: it keeps the exclusion work running, and the exclusion work is what finds the treatable conditions. What to send ahead of an opinion is set out on the practical questions page.

Frequently Asked Questions

What is the difference between mild cognitive impairment and dementia?

Independence. In mild cognitive impairment there is measurable decline — on testing, and noticed by the person or the family — but the person still manages their own money, medicines, transport and meals. In dementia, the decline has begun to take those away. The distinction is clinically important for two practical reasons: it is the threshold at which the syndrome changes its name, and it is the window in which the legal, financial and driving decisions can still be made by the person themselves. It is not a guarantee of outcome either way — some people with mild cognitive impairment remain stable for years, and it is also the stage at which antibody treatment is discussable if the biology is confirmed.

Is a brain scan enough to diagnose it?

Not on its own, and this is worth being clear about because the expectation is common. A structural MRI shows the pattern of atrophy, the burden of small vessel disease, and whether there is a structural or reversible cause — all of which narrow the field considerably. What it does not do is demonstrate Alzheimer's biology. That requires either an amyloid PET scan, cerebrospinal fluid measurement of amyloid and tau, or increasingly a blood phosphorylated tau measurement. Whether any of these is worth doing depends on whether the result would change management, which is a conversation to have with the clinician rather than a test to request.

Should I have biomarker testing if I have no symptoms?

Generally no, and this is a position worth stating plainly. Amyloid pathology can be present for more than a decade before any symptom, and a substantial number of people who think perfectly well carry it. A positive result in someone with no impairment is not a diagnosis of dementia and does not mean decline is inevitable, but it is difficult to un-know and it can affect insurance and employment in ways that vary by jurisdiction. Biomarker testing is most useful when there is a real diagnostic question — an atypical presentation, an unexpectedly young onset, or a decision about antibody treatment — and when the result will be interpreted by someone who will act on it.

How long does the assessment take?

Longer than a single appointment, for a reason that is structural rather than administrative. The defining feature of a dementia is progression, and progression takes two observations separated by time to demonstrate. A good first visit takes the history with someone who knows the person, examines, screens cognition, orders the blood tests and imaging, and reviews the medicines. The results and a second assessment — often three to six months later — are what establish the trajectory. Where the picture is atypical or young-onset, or where a biomarker question is central, the workup is completed in a shorter window because the answers are needed sooner rather than because the definition is different.

Find out whether the workup is complete, and what is still missing

Send clinic letters, any cognitive testing with the scores and dates, imaging reports and the images where you have them, blood test results, and a full medicines list including anything bought over the counter. Our team will return a written opinion on whether the exclusion work is complete, which biomarker question is live in your case, and what can be established from your records before any travel is arranged.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*